Display options
Cite
Byun JH, Jang IS, Kim JW, et al. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood Res. 2016;51(3):171-174doi: 10.5045/br.2016.51.3.171.
Byun, J. H., Jang, I. S., Kim, J. W., & Koh, E. H. (2016). Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood research, 51(3), 171-174. https://doi.org/10.5045/br.2016.51.3.171
Byun, Jung-Hyun, et al. "Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy." Blood research vol. 51,3 (2016): 171-174. doi: https://doi.org/10.5045/br.2016.51.3.171
Byun JH, Jang IS, Kim JW, Koh EH. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy. Blood Res. 2016 Sep;51(3):171-174. doi: 10.5045/br.2016.51.3.171. Epub 2016 Sep 23. PMID: 27722127; PMCID: PMC5054248.
Copy Download .nbib Format: NLM
Share it on

Blood Res. 2016 Sep;51(3):171-174. doi: 10.5045/br.2016.51.3.171. Epub 2016 Sep 23.

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.

Blood research

Jung-Hyun Byun, In-Seok Jang, Jong Woo Kim, Eun-Ha Koh

Affiliations

  1. Department of Laboratory Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Korea.
  2. Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Korea.
  3. Department of Laboratory Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Korea.; Institute of Health Sciences, Gyeongsang National University, Jinju, Korea.

PMID: 27722127 PMCID: PMC5054248 DOI: 10.5045/br.2016.51.3.171

Abstract

BACKGROUND: Unfractionated heparin (UFH) has unstable pharmacokinetics and requires close monitoring. The activated partial thromboplastin time (aPTT) test has been used to monitor UFH therapy for decades in Korea, but its results can be affected by numerous variables. We established an aPTT heparin therapeutic range (HTR) corresponding to therapeutic anti-Xa levels for continuous intravenous UFH administration, and used appropriate monitoring to determine if an adequate dose of UFH was applied.

METHODS: A total of 134

RESULTS: An aPTT range of 87.1 sec to 128.7 sec corresponded to anti-Xa levels of 0.3 IU/mL to 0.7 IU/mL for HTR under our laboratory conditions. Based on their anti-Xa levels, blood specimen distribution were as follows: less than 0.3 IU/mL, 65.7%; 0.3-0.7 IU/mL (therapeutic range), 33.6%; and more than 0.7 IU/mL, 0.7%. No evidence of recurring thromboembolism was observed.

CONCLUSION: Using the conventional aPTT target range may lead to inappropriate dosing of UFH. Transitioning from the aPTT test to the anti-Xa assay is required to avoid the laborious validation of the aPTT HTR test, even though the anti-Xa assay is more expensive.

Keywords: Activated partial thromboplastin time (aPTT); Chromogenic anti-Xa test assay; Heparin therapeutic range (HTR); Unfractionated heparin (UFH)

Conflict of interest statement

Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.

References

  1. Blood Coagul Fibrinolysis. 2005 Apr;16(3):173-6 - PubMed
  2. N Engl J Med. 1972 Aug 17;287(7):324-7 - PubMed
  3. Pharmacotherapy. 2012 Jun;32(6):546-58 - PubMed
  4. J Thromb Haemost. 2009 Jan;7(1):80-6 - PubMed
  5. Am J Clin Pathol. 2013 Apr;139(4):450-6 - PubMed
  6. Thromb Haemost. 2010 Oct;104(4):837-44 - PubMed
  7. Arch Pathol Lab Med. 2014 Nov;138(11):1503-6 - PubMed
  8. Chest. 2012 Feb;141(2 Suppl):e24S-43S - PubMed
  9. Br J Haematol. 2006 Apr;133(1):19-34 - PubMed
  10. Can J Anaesth. 2002 Jun-Jul;49(6):S11-25 - PubMed
  11. Ann Pharmacother. 2011 Jul;45(7-8):861-8 - PubMed

Publication Types